CSL's biosciences sales rise 19% in fiscal 1994
This article was originally published in Clinica
The Biosciences division of CSL (Australia) saw its turnover rise 19% to Au$16.9 million ($13 million) in fiscal 1994 (ended June). CSL says it holds the major market share in Australian blood bank diagnostics and cell culture reagent businesses. The company has developed a diagnostic screening test for TB based on cell-mediated immunity (CMI) technology. "Interim results from clinical trials suggest this new test is superior to existing screening methods," CSL notes in its annual report.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.